OpenAI launches GPT-Rosalind AI model for life sciences research

OpenAI has launched GPT-Rosalind, an AI model designed specifically for life sciences research. The company named it after Rosalind Franklin, the British scientist whose X-ray crystallography work was crucial to discovering DNA's structure.

The model targets biochemistry, drug discovery, and translational medicine research. It can query databases, read scientific papers, connect to other research tools, and suggest new experiments. GPT-Rosalind is built on top of OpenAI's latest internal models and is available through ChatGPT, Codex, and the API for qualified customers.

How does it work?

GPT-Rosalind supports several key research functions that typically require significant time and expertise:

• Evidence synthesis from multiple sources
• Hypothesis generation based on existing research
• Experimental planning and design
• Database queries across scientific literature
• Integration with over 50 scientific tools and data sources

OpenAI is also launching a free Life Sciences research plugin for Codex that connects scientists to these tools and databases. The model is designed to help researchers accelerate the early stages of discovery by handling routine tasks and providing research suggestions.

Why does it matter?

The pharmaceutical and biotech industries are increasingly turning to AI to speed up drug discovery, which traditionally takes over a decade and costs billions of dollars. Major companies including Amgen, Moderna, and Thermo Fisher Scientific are already working with OpenAI to integrate GPT-Rosalind into their research workflows.

This represents a significant push by OpenAI into specialized AI applications beyond general-purpose chatbots. The company is betting that domain-specific models will be more valuable to enterprise customers than general-purpose tools. For researchers, the model could reduce the time spent on literature reviews and experimental planning, allowing them to focus on actual discovery work.

The context

GPT-Rosalind comes just days after OpenAI announced GPT-5.4-Cyber, a model fine-tuned for cybersecurity work. This pattern of releasing specialized models reflects growing competition in the AI space, particularly with Anthropic's recent announcement of its Mythos frontier AI model.

The timing is significant for the life sciences industry, which has seen a surge in AI adoption since the COVID-19 pandemic demonstrated the potential for accelerated research timelines. Traditional drug discovery processes remain slow and expensive, with high failure rates that AI tools promise to improve through better target identification and hypothesis testing.